文献速递浆细胞疾病

新诊断标危多发性骨髓瘤患者的亚分层

Substratification of patients with newly diagnosed standard-risk multiple myeloma.
PubMed 文献 · Br J Haematol · 2019-02-15

该研究分析1461例新诊断多发性骨髓瘤患者,56%为标危。标危患者中,高龄、体重指数极端值、非超二倍体核型和淋巴细胞计数异常与较差总生存相关;≥2个不良因素者占17%,其总生存与高危患者相当(HR 0.91,95%CI 0.67-1.24,P=0.548)。

要点

  • 标危多发性骨髓瘤患者中约六分之一总生存与高危患者相当。
  • 标危患者中高龄、体重指数极端值、非超二倍体核型及淋巴细胞计数异常与较差总生存相关。
  • 采用评分分组较ISS分期能更好预测标危患者预后。

核心结论

  • 标危多发性骨髓瘤患者为异质性群体,其中约六分之一总生存与高危疾病相当,可用易获得的患者和疾病特征识别高危患者。

研究设计与样本

  • 研究纳入1461例新诊断多发性骨髓瘤患者,分析标危患者中预测高危表型的患者和疾病特征。

主要发现

  • 全部患者中56%表现为标危疾病,标危患者中高龄、体重指数极端值、非超二倍体核型和淋巴细胞计数异常与较差总生存相关。
  • 标危患者中0-1个不良因素者较高危患者总生存更好(HR 0.32,95%CI 0.24-0.43,P<0.001)。
  • 标危患者中2个不良因素者较高危患者总生存更好(HR 0.54,95%CI 0.41-0.72,P<0.001)。
  • 17%的标危患者存在≥2个不良因素,其总生存与高危患者相当(HR 0.91,95%CI 0.67-1.24,P=0.548)。
  • 在标危患者中,采用评分分组较ISS分期预测能力提高。

关键数值与推荐

  • 标危患者中0-1个不良因素较高危患者总生存更好(HR 0.32,95%CI 0.24-0.43,P<0.001)。
  • 标危患者中2个不良因素较高危患者总生存更好(HR 0.54,95%CI 0.41-0.72,P<0.001)。
  • 标危患者中≥2个不良因素者总生存与高危患者相当(HR 0.91,95%CI 0.67-1.24,P=0.548)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Among them, advanced age, extremes of body mass index, non-hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard-risk patients with 0-1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24-0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41-0·72, P < 0·001) experienced better OS than high-risk patients. Two or more adverse factors were present in 17% of standard-risk patients and were associated with OS comparable to high-risk patients (HR 0·91, 95% CI 0·67-1·24, P = 0·548). Predictive power among standard-risk patients was improved using score groups compared to ISS stages. Patients with standard-risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high-risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Binder M, Rajkumar SV, Ketterling RP, et al. Substratification of patients with newly diagnosed standard-risk multiple myeloma. Br J Haematol. 2019. PMID: 30768679. doi:10.1111/bjh.15800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。